Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Biochemical markers in persons with preclinical familial Alzheimer disease.

Ringman JM, Younkin SG, Pratico D, Seltzer W, Cole GM, Geschwind DH, Rodriguez-Agudelo Y, Schaffer B, Fein J, Sokolow S, Rosario ER, Gylys KH, Varpetian A, Medina LD, Cummings JL.

Neurology. 2008 Jul 8;71(2):85-92. doi: 10.1212/01.wnl.0000303973.71803.81. Epub 2008 May 28.

PMID:
18509095
2.

Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations.

Ringman JM, Schulman H, Becker C, Jones T, Bai Y, Immermann F, Cole G, Sokolow S, Gylys K, Geschwind DH, Cummings JL, Wan HI.

Arch Neurol. 2012 Jan;69(1):96-104. doi: 10.1001/archneurol.2011.642.

3.

Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease.

Ringman JM, Coppola G, Elashoff D, Rodriguez-Agudelo Y, Medina LD, Gylys K, Cummings JL, Cole GM.

Dement Geriatr Cogn Disord. 2012;33(1):1-5. doi: 10.1159/000335729. Epub 2012 Feb 13.

4.

PSEN1 mutation carriers present lower cerebrospinal fluid amyoid-β42 levels than sporadic early-onset Alzheimer's disease patients but no differences in neuronal injury biomarkers.

Balasa M, Vidal-Piñeiro D, Lladó A, Antonell A, Bosch B, Castellanos F, Bargalló N, Bartres-Faz D, Molinuevo JL, Sánchez-Valle R.

J Alzheimers Dis. 2012;30(3):605-16. doi: 10.3233/JAD-2012-111949.

PMID:
22426017
5.

Plasma methionine sulfoxide in persons with familial Alzheimer's disease mutations.

Ringman JM, Fithian AT, Gylys K, Cummings JL, Coppola G, Elashoff D, Pratico D, Moskovitz J, Bitan G.

Dement Geriatr Cogn Disord. 2012;33(4):219-25. doi: 10.1159/000338546. Epub 2012 May 14.

6.

Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study.

Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gutierrez Gomez M, Langois CM, Langbaum JB, Roontiva A, Thiyyagura P, Lee W, Ayutyanont N, Lopez L, Moreno S, Muñoz C, Tirado V, Acosta-Baena N, Fagan AM, Giraldo M, Garcia G, Huentelman MJ, Tariot PN, Lopera F, Reiman EM.

JAMA Neurol. 2015 Mar;72(3):316-24. doi: 10.1001/jamaneurol.2014.3314.

7.

Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype.

Ringman JM, Elashoff D, Geschwind DH, Welsh BT, Gylys KH, Lee C, Cummings JL, Cole GM.

Arch Neurol. 2012 Jun;69(6):757-64. doi: 10.1001/archneurol.2012.277.

8.

Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM.

Arch Neurol. 2007 Mar;64(3):343-9. Epub 2007 Jan 8.

PMID:
17210801
9.

Cerebrospinal fluid biomarkers in Alzheimer's disease families with PSEN1 mutations.

Fortea J, Lladó A, Bosch B, Antonell A, Oliva R, Molinuevo JL, Sánchez-Valle R.

Neurodegener Dis. 2011;8(4):202-7. doi: 10.1159/000322229. Epub 2011 Jan 5.

PMID:
21212633
10.

Increased prevalence of significant recurrent headache in preclinical familial Alzheimer's disease mutation carriers.

Ringman JM, Romano JD, Medina LD, Rodriguez-Agudelo Y, Schaffer B, Varpetian A, Ortiz F, Fitten LJ, Cummings JL, Baloh RW.

Dement Geriatr Cogn Disord. 2008;25(4):380-4. doi: 10.1159/000121986. Epub 2008 Mar 29.

PMID:
18376127
11.

Detecting Alzheimer disease before it happens: The key to prevention?

Quinn J, Sabbagh MN.

Neurology. 2008 Jul 8;71(2):78-9. doi: 10.1212/01.wnl.0000316808.21277.69. No abstract available.

PMID:
18606962
12.

Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease.

Thordardottir S, Ståhlbom AK, Ferreira D, Almkvist O, Westman E, Zetterberg H, Eriksdotter M, Blennow K, Graff C.

J Alzheimers Dis. 2015;43(4):1393-402. doi: 10.3233/JAD-140339.

PMID:
25182737
13.

Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study.

Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez-Del-Rio M, Fagan AM, Shah AR, Alvarez S, Arbelaez A, Giraldo M, Acosta-Baena N, Sperling RA, Dickerson B, Stern CE, Tirado V, Munoz C, Reiman RA, Huentelman MJ, Alexander GE, Langbaum JB, Kosik KS, Tariot PN, Lopera F.

Lancet Neurol. 2012 Dec;11(12):1048-56. doi: 10.1016/S1474-4422(12)70228-4. Epub 2012 Nov 6.

14.

Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers.

Schöll M, Wall A, Thordardottir S, Ferreira D, Bogdanovic N, Långström B, Almkvist O, Graff C, Nordberg A.

Neurology. 2012 Jul 17;79(3):229-36. doi: 10.1212/WNL.0b013e31825fdf18. Epub 2012 Jun 13.

PMID:
22700814
15.

Relative ratio and level of amyloid-β 42 surrogate in cerebrospinal fluid of familial Alzheimer disease patients with presenilin 1 mutations.

Tagami S, Okochi M, Yanagida K, Kodama T, Arai T, Kuwano R, Ikeuchi T, Takeda M.

Neurodegener Dis. 2014;13(2-3):166-70. doi: 10.1159/000355258. Epub 2013 Oct 30.

PMID:
24192669
16.

Apolipoprotein E epsilon4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer disease.

Desikan RS, McEvoy LK, Holland D, Thompson WK, Brewer JB, Aisen PS, Andreassen OA, Hyman BT, Sperling RA, Dale AM; Alzheimer's Disease Neuroimaging Initiative.

AJNR Am J Neuroradiol. 2013 Mar;34(3):505-10. doi: 10.3174/ajnr.A3267. Epub 2012 Sep 13.

17.

Marking the markers of Alzheimer's: too good to diagnose, too bad to use?

Olah Z, Pakaski M, Janka Z, Kalman J.

Neuropsychopharmacol Hung. 2012 Sep;14(3):165-76. Review.

18.

BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.

Mulder SD, van der Flier WM, Verheijen JH, Mulder C, Scheltens P, Blankenstein MA, Hack CE, Veerhuis R.

J Alzheimers Dis. 2010;20(1):253-60. doi: 10.3233/JAD-2010-1367.

PMID:
20164582
19.

Enzymatic characteristics of I213T mutant presenilin-1/gamma-secretase in cell models and knock-in mouse brains: familial Alzheimer disease-linked mutation impairs gamma-site cleavage of amyloid precursor protein C-terminal fragment beta.

Shimojo M, Sahara N, Mizoroki T, Funamoto S, Morishima-Kawashima M, Kudo T, Takeda M, Ihara Y, Ichinose H, Takashima A.

J Biol Chem. 2008 Jun 13;283(24):16488-96. doi: 10.1074/jbc.M801279200. Epub 2008 Apr 21.

20.

Supportive CSF biomarker evidence to enhance the National Institute on Aging-Alzheimer's Association criteria for diagnosis of Alzheimer's type dementia--a study from Southern India.

Huded CB, Bharath S, Chandra SR, Sivakumar PT, Varghese M, Subramanian S.

Asian J Psychiatr. 2015 Feb;13:44-7. doi: 10.1016/j.ajp.2014.10.007. Epub 2014 Nov 6.

PMID:
25468261

Supplemental Content

Support Center